Management of bone disease in patients undergoing hormonal therapy for breast cancer.
Endocrinol Metab Clin North Am
; 40(3): 549-62, viii, 2011 Sep.
Article
em En
| MEDLINE
| ID: mdl-21889720
Estrogen deficiency at menopause is associated with increased risk of bone loss and osteoporosis. Aromatase inhibitors (AIs) are increasingly being used for the treatment of postmenopausal hormone-sensitive breast cancer because of better disease-free survival compared with tamoxifen seen in clinical trials with AIs. This article reviews the effect of endocrine therapies of breast cancer on bone and the management of bone disease with these endocrine therapies. The effect of these therapies on bone mineral density and bone turnover along with possible interventions is discussed. AIs are also associated with skeletal-related events, which are not discussed.
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Doenças Ósseas
/
Neoplasias da Mama
/
Carcinoma
/
Antineoplásicos Hormonais
Tipo de estudo:
Evaluation_studies
Limite:
Animals
/
Female
/
Humans
Idioma:
En
Revista:
Endocrinol Metab Clin North Am
Assunto da revista:
ENDOCRINOLOGIA
/
METABOLISMO
Ano de publicação:
2011
Tipo de documento:
Article
País de afiliação:
Estados Unidos